Alexion Pharmaceuticals Inc. (ALXN) |
|
114.43 1.97 (1.75%)
|
10-01 08:48 |
|
Open: |
113.13 |
Pre. Close: |
112.46 |
|
High:
|
115 |
Low:
|
112.85 |
|
Volume:
|
1,655,430 |
Market Cap:
|
25,080M |
|
|
|
|
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees. The firm is focused on the development and commercialization of therapeutic products. The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
115.164 - 115.809 |
115.809 - 116.4 |
|
Low:
|
111.131 - 111.983 |
111.983 - 112.763 |
|
Close:
|
113.198 - 114.431 |
114.431 - 115.559 |
|
Technical analysis |
as of: 2020-09-30 4:38:32 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 141.11 One year: 164.81 |
| Support: |
Support1: 109.49 Support2: 102.50 |
| Resistance: |
Resistance1: 120.81 Resistance2: 141.11 |
| Pivot: |
112.36 |
| Moving Average: |
MA(5): 113.33 MA(20): 112.01
MA(100): 108.85 MA(250): 104.91 |
| MACD: |
MACD(12,26): 1.74 Signal(9): 1.79  |
| Stochastic oscillator: |
%K(14,3): 57.77 %D(3): 58.18 |
| RSI: |
RSI(14): 57.24 |
| 52-week: |
High: 121.50 Low: 72.67 Change(%): 15.4 |
| Average Vol(K): |
3-Month: 188889 10-Days: 206064 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.ALXN has closed below upper band by 33.7%. Bollinger Bands are 3.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Wed, 30 Sep 2020
Alexion Pharmaceuticals Inc. (ALXN) is primed for evolution with the beta value of 1.31 - The InvestChronicle
Wed, 30 Sep 2020
Alexion Pharmaceuticals Inc. (ALXN): Skating on Thin Ice? We Know the Answer - The News Heater
Wed, 30 Sep 2020
Short Interest On Alexion Pharmaceuticals, Inc. (ALXN) Might Be Rising - Invest Million
Tue, 29 Sep 2020
Alexion Pharmaceuticals Inc. (ALXN) is 5.85% away from 50-day simple Moving Average despite all headwinds - News Daemon
Fri, 25 Sep 2020
Alexion Pharmaceuticals Inc. (ALXN) Reveals an Earnings Mystery - newsheater.com
Mon, 21 Sep 2020
Alexion Pharmaceuticals Inc. (ALXN) Open at price of $114.39: A Brand-New Opportunity for Investors - News Daemon
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
|
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
219 |
| Shares Float (M) |
219 |
|
% Held by Insiders
|
0.30 |
|
% Held by Institutions
|
95.39 |
|
Shares Short (K)
|
4,840 |
|
Shares Short P. Month (K)
|
4,410 |
Stock Financials |
|
EPS
|
3.810 |
|
EPS Est This Year
|
5.620 |
|
EPS Est Next Year
|
7.130 |
|
Book Value (p.s.)
|
47.880 |
|
Profit Margin
|
15.28 |
|
Operating Margin
|
46.40 |
|
Return on Assets (ttm)
|
10.3 |
|
Return on Equity (ttm)
|
8.2 |
|
Qtrly Rev. Growth
|
20.1 |
|
Gross Profit (p.s.)
|
20.988 |
|
Sales Per Share
|
25.277 |
|
EBITDA (p.s.)
|
13.277 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
2,460 |
|
Levered Free Cash Flow (M)
|
1,690 |
Stock Valuations |
|
PE Ratio
|
30.03 |
|
PEG Ratio
|
0.74 |
|
Price to Book value
|
2.39 |
|
Price to Sales
|
4.53 |
|
Price to Cash Flow
|
10.19 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
